4D Molecular Therapeutics Reports FY2025 Financials and Major Operational Milestones

Summary of Key Points

• Completed enrollment in 4D-150 4FRONT-1 Wet AMD Phase 3 trial well ahead of schedule; topline data expected H1 2027.
• Strong progress in clinical pipeline, including upcoming data readouts and trial initiations in both wet AMD and diabetic macular edema (DME).
• Entered strategic partnership with Otsuka Pharmaceutical for 4D-150 in the Asia-Pacific region, securing substantial non-dilutive funding and potential milestones.
• Significantly strengthened balance sheet, ending 2025 with \$514 million in cash and equivalents, extending runway into H2 2028.
• Raised \$118 million through multiple financings, including investment from Cystic Fibrosis Foundation.
• Delivered positive long-term results for 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease.

Detailed Operational and Financial Update

Clinical Pipeline and Milestones

• 4D-150 (Wet Age-Related Macular Degeneration & Diabetic Macular Edema)
  • Completed enrollment for 4FRONT-1 Phase 3 trial in North America with over 500 patients randomized—well ahead of initial projections, reflecting strong physician and patient interest.
  • Topline data from 4FRONT-1 expected in the first half of 2027. Enrollment for 4FRONT-2 (global trial) is accelerating and expected to complete in H2 2026, with topline results in H2 2027.
  • Increased target enrollment for both Phase 3 trials to 480 patients each, providing approximately 90% power for statistical significance with regulatory agency alignment.
  • Two-year Phase 2b PRISM data for wet AMD (in a broader patient population) expected mid-2026; two-year SPECTRA data for DME expected in H2 2026.
  • Global Phase 3 trial for DME expected to initiate in Q3 2026.
  • Interim data continues to show durable benefit, maintenance of visual acuity, control of retinal anatomy, and reduced treatment burden. No new safety or intraocular inflammation events reported with up to 3.5 years of follow-up.
• 4D-710 (Cystic Fibrosis Lung Disease)
  • Positive interim results from the AEROW Phase 1/2 trial, demonstrating clinically meaningful lung function improvements and durable CFTR gene expression through at least one year at the selected dose.
  • Phase 2 trial is ongoing and fully funded by the Cystic Fibrosis Foundation. Program update expected in H2 2026.

Strategic Partnerships and Financial Strength

• Otsuka Pharmaceutical Partnership
  • 4DMT received an \$85 million upfront cash payment in Q4 2025 for 4D-150 rights in the Asia-Pacific region.
  • Company expects at least \$50 million in Otsuka cost-sharing over the next three years to support global registration.
  • Potential to receive up to \$336 million in regulatory and commercial milestone payments, plus tiered double-digit royalties.
  • 4DMT retains full development and commercialization rights for 4D-150 outside Asia-Pacific, including the U.S., Europe, and Latin America.
• Other Financing Highlights
  • Equity investment from the CF Foundation of up to \$11 million (with \$7.5 million received upfront) to accelerate 4D-710 development.
  • Raised \$10 million via at-the-market equity facility in October 2025.
  • Raised \$100 million in a November 2025 equity offering (approximately \$93 million net proceeds).
  • Cash, cash equivalents, and marketable securities stood at \$514 million as of December 31, 2025—sufficient to fund operations into H2 2028, including anticipated Otsuka payments.
• Leadership and Organizational Growth
  • Expanded Board and executive team to strengthen late-stage execution and commercial readiness. Notable appointments include Glenn P. S as Board Director, Kristian Humer as CFO, Julie Clark, M.D. as Chief Medical Officer, Katy Barglow, Ph.D. as Chief Technical Officer, Kim Maplestone as Chief Clinical Operations Officer, and expanded role for Chris Simms as Chief Commercial & Business Officer.

Financial Results

• Collaboration and license revenue: \$85.2 million for 2025 (up from \$0.04 million in 2024), primarily due to the Otsuka upfront payment.
• R&D expenses: \$195.7 million (up from \$141.3 million in 2024), reflecting acceleration of Phase 3 trial activities.
• G&A expenses: \$49.1 million (up from \$46.6 million in 2024).
• Net loss: \$140.1 million for 2025 (improved from \$160.9 million loss in 2024).
• Total assets: \$566.7 million as of December 31, 2025.
• Total liabilities: \$61.0 million.
• Accumulated deficit: \$716.3 million.
• Weighted-average shares outstanding: 57.9 million.

Potential Price-Sensitive Information for Shareholders

• Accelerated clinical progress in wet AMD with early Phase 3 enrollment completion could increase confidence in 4D-150’s commercial prospects.
• Upcoming pivotal data readouts in 2026-2027, including multiple Phase 2 and Phase 3 studies, represent significant catalysts for the share price.
• Balance sheet strength and multi-year runway reduce financing risk, which is positive for shareholders.
• Otsuka partnership significantly derisks Asian market entry and brings in non-dilutive capital plus potential for substantial future milestone and royalty payments.
• Positive long-term data for both lead programs and strong safety profile support the long-term value proposition.
• Leadership expansion and commercial readiness signal preparation for potential product launches.

Conclusion

4D Molecular Therapeutics delivered a transformative year in 2025, marked by robust clinical progress, major strategic partnerships, and a fortified financial foundation. The company is well-positioned for significant clinical and commercial milestones in 2026 and beyond, with multiple data readouts and a strong runway to support its pivotal programs. The anticipated topline results from the 4D-150 Phase 3 program in wet AMD, expanded late-stage pipeline in DME and CF, and substantial non-dilutive financing through partnerships and fundraising activities all point to potential catalysts that could materially impact the company’s valuation and shareholder returns.

Disclaimer

This news article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. The information is based on company-reported data and may contain forward-looking statements subject to risks and uncertainties. Investors should perform their own due diligence and consult their financial advisor before making investment decisions.

View 4D Molecular Therapeutics, Inc. Historical chart here